MLTX News and Press, MoonLake Immunotherapeutics From 02/02/26

The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe  palmoplantar pustulosis (PPP) supported by positive results from the Phase 2 LEDA trial The upcoming Phase 3 program will therefore be ex...

2026-01-15 11:23:48 ET More on MoonLake Immunotherapeutics MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission MoonLake: Ignore The Panic, Catch The Upside MoonLake surges as no additional studies are required for lead drug Seeking Alpha...

2026-01-14 18:05:09 ET from Goldman Sachs issued a price target of $10.00 for MLTX on 2026-01-14 22:09:25. The adjusted price target was set to $10.00. At the time of the announcement, MLTX was trading at $17.41. The overall price target consensus is at $18.88 with high ...

2026-01-14 17:15:04 ET Goldman Sachs analyst issues SELL recommendation for MLTX on January 14, 2026 10:09PM ET. The previous analyst recommendation was Mixed. MLTX was trading at $17.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

2026-01-09 08:15:00 ET Thesis Read the full article on Seeking Alpha For further details see: MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission

2026-01-09 06:15:23 ET BTIG analyst issues BUY recommendation for MLTX on January 9, 2026 10:58AM ET. The previous analyst recommendation was Neutral. MLTX was trading at $14.34 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...

2026-01-08 09:05:32 ET from UBS issued a price target of $45.00 for MLTX on 2026-01-08 13:49:04. The adjusted price target was set to $45.00. At the time of the announcement, MLTX was trading at $14.3828. The overall price target consensus is at $17.29 with high price of...

2026-01-08 08:24:31 ET More on MoonLake Immunotherapeutics MoonLake: Ignore The Panic, Catch The Upside Seeking Alpha’s Quant Rating on MoonLake Immunotherapeutics Historical earnings data for MoonLake Immunotherapeutics Financial information for MoonL...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application (BLA) for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS) FDA feedback confirms that ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in MoonLake between March 10, 2024 and September...